Praxis Precision Medicines (PRAX) Cash & Equivalents (2019 - 2026)

Praxis Precision Medicines has reported Cash & Equivalents for 8 years, with the latest figure at $536.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 223.94% year-over-year to $536.3 million; the trailing twelve-month figure through Mar 2026 stood at $536.3 million (up 223.94% YoY), and the FY2025 full-year result was $357.3 million, up 65.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $536.3 million, up from $357.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $536.3 million in Q1 2026, with the low at $56.0 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $158.4 million, with a median of $145.1 million recorded in 2024.
• Year-over-year, Cash & Equivalents plunged 68.14% in 2022 and jumped 223.94% in 2026.
• Tracing PRAX's Cash & Equivalents over 5 years: stood at $61.6 million in 2022, then surged by 31.95% to $81.3 million in 2023, then soared by 164.91% to $215.4 million in 2024, then jumped by 65.91% to $357.3 million in 2025, then jumped by 50.1% to $536.3 million in 2026.
• The last three Cash & Equivalents figures came in at $536.3 million (Q1 2026), $357.3 million (Q4 2025), and $149.5 million (Q3 2025), per Business Quant data.

Peer Comparison